Pfizer Inc. (NYSE:PFE) Shares Sold by Rodgers Brothers Inc.

Rodgers Brothers Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,303 shares of the biopharmaceutical company’s stock after selling 1,075 shares during the period. Rodgers Brothers Inc.’s holdings in Pfizer were worth $1,016,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. United Bank raised its position in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 1,277 shares during the last quarter. Fred Alger Management LLC increased its stake in Pfizer by 7.4% during the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company’s stock worth $2,971,000 after buying an additional 7,076 shares in the last quarter. Tradition Wealth Management LLC raised its holdings in shares of Pfizer by 4.5% during the third quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 1,099 shares during the last quarter. Bellevue Group AG lifted its position in shares of Pfizer by 59.2% in the third quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company’s stock valued at $4,083,000 after acquiring an additional 52,461 shares in the last quarter. Finally, Semmax Financial Advisors Inc. boosted its stake in shares of Pfizer by 3.2% in the third quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company’s stock worth $2,695,000 after acquiring an additional 3,185 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on PFE shares. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Price Performance

PFE stock opened at $25.20 on Monday. The company has a market capitalization of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average price is $26.06 and its 200 day moving average price is $26.90.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.